James Smith, MD
Cardiovascular Disease · Tampa, FLNPI 1811977333
Payments from drug & device makers
Across 608 payments — averaging $549.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$105K
- Amgen$91K
- Boehringer Ingelheim$49K
- Esperion Therapeutics, Inc.$31K
- Sanofi-aventis U.S. LLC$14K
- AstraZeneca$11K
- plus $35K from 31 others
Across 1 payment — averaging $49.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$49
What the payments were for
- Consulting fees$11,5104%
- Speaking & faculty fees$283,52587%
- Travel & lodging$12,8234%
- Food & beverage$16,2755%
- Education$990%
- Gifts$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 72 | $104,631 |
| Amgen | 114 | $90,510 |
| Boehringer Ingelheim | 42 | $48,543 |
| Esperion Therapeutics, Inc. | 41 | $30,937 |
| Sanofi-aventis U.S. LLC | 21 | $13,951 |
| AstraZeneca(2 entities) | 46 | $10,563 |
| Bayer | 6 | $9,680 |
| Shockwave Medical, Inc | 12 | $8,398 |
| Lilly USA, LLC | 6 | $5,365 |
| Regeneron Healthcare Solutions, Inc. | 10 | $4,139 |
| Abiomed | 44 | $2,532 |
| Cardiovascular Systems Inc. | 37 | $954 |
| Medtronic(2 entities) | 40 | $918 |
| Abbott | 9 | $534 |
| Novartis | 29 | $470 |
| Boston Scientific | 10 | $355 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $284 |
| Inari Medical, Inc. | 2 | $210 |
| AbbVie | 1 | $162 |
| Johnson & Johnson | 12 | $159 |
| Actelion Pharmaceuticals US, Inc. | 3 | $138 |
| Alnylam Pharmaceuticals Inc. | 4 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Novo Nordisk | 4 | $84 |
| Kowa Pharmaceuticals America, Inc. | 5 | $69 |
| Amarin Pharma, Inc. | 3 | $54 |
| Biotronik Inc. | 2 | $43 |
| United Therapeutics Corporation | 2 | $39 |
| Merck | 2 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Elutia, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Preventice Services, LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Livanova USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$96,961
- Repatha$89,320
- JARDIANCE$53,435
- NEXLIZET$30,567
- NEXLETOL$30,567
- PRALUENT$17,458
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,219
- FARXIGA$7,849
- VELSIPITY$2,800
- VYNDAMAX$1,654
- Impella$1,101
- Diamondback Peripheral$412
- FLOWTRIEVER CATHETER, S$400
- BOTOX$162
- Diamondback Coronary$153
- COROFLOW$125
- Kerendia$125
- Resolute$121
- EVKEEZA$121
- AVVIGO Guidance System$119
How this compares
$334,090 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 84 | $114,951 |
| EntrestoSacubitril/Valsartan | 40 | $63,291 |
| EliquisApixaban | 51 | $62,568 |
| XareltoRivaroxaban | 20 | $30,538 |
| FarxigaDapagliflozin Propanediol | 33 | $30,316 |
| Praluent PenAlirocumab | 18 | $13,606 |
| OzempicSemaglutide | 11 | $10,715 |
| MyrbetriqMirabegron | 13 | $6,873 |
| Clonidine | 12 | $2,344 |
| Rosuvastatin Calcium | 191 | $2,225 |
| Ranolazine ErRanolazine | 13 | $1,873 |
| Ezetimibe | 70 | $1,695 |
| ClopidogrelClopidogrel Bisulfate | 139 | $1,360 |
| Atorvastatin Calcium | 125 | $1,242 |
| Digoxin | 27 | $889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $470 | $63,29140 claims |
| PfizerEliquis | $104,631 | $62,56851 claims |
| Johnson & JohnsonXarelto | $159 | $30,53820 claims |
| AstraZenecaFarxiga | $10,563 | $30,31633 claims |
| Novo NordiskOzempic | $84 | $10,71511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tampa
- Hiram BezerraTampa$1.6M
- Arthur LabovitzTampa$689K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.